Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

Abstract

Efforts to selectively target and disrupt established tumor vasculature have largely failed to date. We hypothesized that a vaccinia virus engineered to target cells with activation of the ras/MAPK signaling pathway (JX-594) could specifically infect and express transgenes (hGM-CSF, b-galactosidase) in tumor-associated vascular endothelial cells in humans. Efficient replication and transgene expression in normal human endothelial cells in vitro required either VEGF or FGF-2 stimulation. Intravenous infusion in mice resulted in virus replication in tumor-associated endothelial cells, disruption of tumor blood flow, and hypoxia within 48 hours; massive tumor necrosis ensued within 5 days. Normal vessels were not affected. In patients treated with intravenous JX-594 in a phase I clinical trial, we showed dose-dependent endothelial cell infection and transgene expression in tumor biopsies of diverse histologies. Finally, patients with advanced hepatocellular carcinoma, a hypervascular and VEGF-rich tumor type, were treated with JX-594 on phase II clinical trials. JX-594 treatment caused disruption of tumor perfusion as early as 5 days in both VEGF receptor inhibitor-na€ ve and -refractory patients. Toxicities to normal blood vessels or to wound healing were not evident clinically or on MRI scans. This platform technology opens up the possibility of multifunctional engineered vaccinia products that selectively target and infect tumorassociated endothelial cells, as well as cancer cells, resulting in transgene expression, vasculature disruption, and tumor destruction in humans systemically. Cancer Res; 73(4); 1265-75. Ó2012 AACR.

Primary Human Leukocyte Subsets Differentially Express Vaccinia Virus Receptors Enriched in Lipid Rafts

“…The success of these poxvirus-based vaccines greatly renews research interests in poxvirus biology and virology. Because VV replication is dependent on epidermal growth factor receptor (EGFR)/Ras pathway signaling, which is commonly active in epithelial cancers (37), VV has been developed as a promising oncolytic agent to kill tumor cells and has been engineered as a vehicle for the intravenous delivery and expression of antitumor siRNA and peptides (37)(38)(39). Therefore, characterization of VV binding and infection tropism will also advance the concept of using live viruses to treat cancer.…”

GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment

“…Targeting tumor-associated angiogenesis is an important goal in cancer therapy; however, the efficient delivery of drugs to the endothelial cells of the tumor vasculature remains an important issue in antiangiogenesis therapy. 6,7 Numerous targeting moieties have been used for target-specific delivery of antiangiogenesis therapies, including small…”

Fighting Cancer with Mathematics and Viruses

“…Targeting of tumor vasculature by oncolytic viruses has been observed [114,115] and was recently explained by suppression of cell-intrinsic antiviral mechanisms via vascular endothelial growth factor (VEGF) in the tumor microenvironment [116]. This could add to the anti-tumor potency of oncolytic virotherapy by inducing subsequent nutrient deprivation and hypoxia, but also impair viral delivery to the tumor site, warranting careful assessment prior to manipulating the anti-endothelial potential of an oncolytic vector to enhance clinical benefit.…”